To include your compound in the COVID-19 Resource Center, submit it here.

CRLX101: Phase II started

Cerulean began an open-label, Russian and Ukrainian Phase II trial to compare CRLX101

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE